Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Joanne B, Fertig"'
Autor:
Megan L. Ryan, Stephanie S. O’Malley, Joanne B. Fertig, Raye Z. Litten, Daniel E. Falk, Srinivas B. Muvvala, Hayley Treloar Padovano, Ran Wu, Thomas H. Chun, Robert Miranda
Publikováno v:
Alcohol Clin Exp Res
BACKGROUND: The alcohol cue reactivity paradigm is increasingly used to screen medications for the treatment of alcohol use disorder (AUD) and other substance use disorders. Yet, its prospective association with craving and naturalistic drinking outc
Publikováno v:
Alcoholism: Clinical and Experimental Research. 44:23-35
Autor:
Megan L. Ryan, Raymond F. Anton, Joanne B. Fertig, Jennifer Scodes, Francoise Trinquet, Keith Isenberg, Daniel E. Falk, Karl Mann, Rebecca L. Robinson, Henry R. Kranzler, Charles A. O'Brien, Bernard L. Silverman, David J. McCann, Roger E. Meyer, Conrad J. Wong, Katie Witkiewitz, Melanie M. Wall, Didier Meulien, Deborah S. Hasin, Benjamine Zakine, Stephanie S. O'Malley, Raye Z. Litten
Publikováno v:
The Lancet Psychiatry. 4:469-476
Summary Background Alcohol dependence is often untreated. Although abstinence is often the aim of treatment, many drinkers prefer drinking reduction goals. Therefore, if supported by evidence of benefit, drinking reduction goals could broaden the app
Publikováno v:
Substance Use Disorders ISBN: 9783030336783
Compared to other medical disorders, including other brain diseases, the number of medications approved for alcohol use disorder (AUD) is very small. Disulfiram, naltrexone (oral and long-acting), and acamprosate are approved by the US Food and Drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ea7bc554f53caa507fee90cd799945b
https://doi.org/10.1007/164_2019_295
https://doi.org/10.1007/164_2019_295
Autor:
Joanne B. Fertig, Eric Devine, Charles Scott, Gantt P. Galloway, Alan I. Green, Ihsan M. Salloum, Steven Shoptaw, Kyle M. Kampman, John Mendelson, Catherine Brooks, Kelly E. Dunn, Erik W. Gunderson, Nassima Ait-Daoud Tiouririne, Eric C. Strain, Raye Z. Litten, Heather Burns, Steven Caras, Lorenzo Leggio, Mary F. Brunette, Janet Ransom, Richard N. Rosenthal, Barbara J. Mason, Megan L. Ryan, Ricardo Cruz, Lara A. Ray, D. Jeffrey Newport, E. Sherwood Brown, Daniel E. Falk
Publikováno v:
Alcoholism: Clinical and Experimental Research.
BACKGROUND: Several single-site alcohol treatment clinical trials have demonstrated efficacy for immediate-release (IR) gabapentin in reducing drinking outcomes among individuals with alcohol dependence. The purpose of this study was to conduct a lar
Autor:
Eric C. Strain, Nassima Ait-Daoud, Charles Scott, Beatrice Rendenbach-Mueller, George F. Koob, Laurie Sickles-Colaneri, Daniel E. Falk, Kelly E. Dunn, Elizabeth M. Mahoney, Raye Z. Litten, Joanne B. Fertig, Katherine A. Tracy, Kyle M. Kampman, David A. Katz, Domenic A. Ciraulo, Janet Ransom, Bankole A. Johnson, Megan L. Ryan
Publikováno v:
Neuropsychopharmacology. 42:1012-1023
Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. Thi
Publikováno v:
Alcoholism: Clinical and Experimental Research. 40:1368-1379
For more than 25 years, advances have been made in developing medications to treat alcohol use disorder (AUD), highlighted by the U.S. Food and Drug Administration’s (FDA’s) approval of naltrexone (oral and long-acting) and acamprosate. Despite t
Publikováno v:
Journal of Addiction Medicine. 9:296-303
Objectives: To explore whether varenicline (Chantix) showed more efficacy in treating certain subgroups of patients. In a recent multisite trial, varenicline was shown to be effective in reducing drinking in alcohol-dependent patients, both smokers a
Publikováno v:
The Neuropharmacology of Alcohol ISBN: 9783319965222
For more than 25 years, researchers have made advances in developing medications to treat alcohol use disorder (AUD), highlighted by the US Food and Drug Administration’s (FDA’s) approval of disulfiram, naltrexone (oral and long-acting), and acam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cae1d14f25d0829cd0a11ebcff177ce2
https://doi.org/10.1007/164_2017_79
https://doi.org/10.1007/164_2017_79
Autor:
Joanne B. Fertig, Megan L. Ryan, Bankole A. Johnson, Karl Mann, Daniel E. Falk, Deborah S. Hasin, Katie Witkiewitz, Henry R. Kranzler, Raye Z. Litten, Raymond F. Anton, Stephanie S. O'Malley, Didier Meulien, Megan Slater
Publikováno v:
JAMA Psychiatry. 76:374
IMPORTANCE: The US Food and Drug Administration recognizes total abstinence and no heavy drinking days as outcomes for pivotal pharmacotherapy trials for alcohol use disorder (AUD). Many patients have difficulty achieving these outcomes, which can di